4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of GBP 152.45 million. The enterprise value is 132.84 million.

Market Cap	152.45M
Enterprise Value	132.84M

Important Dates

The last earnings date was Wednesday, June 11, 2025.

Earnings Date	Jun 11, 2025
Ex-Dividend Date	n/a

Share Statistics

4basebio has 15.48 million shares outstanding. The number of shares has increased by 6.47% in one year.

Current Share Class	15.48M
Shares Outstanding	15.48M
Shares Change (YoY)	+6.47%
Shares Change (QoQ)	+6.41%
Owned by Insiders (%)	14.00%
Owned by Institutions (%)	31.70%
Float	6.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	163.40
PB Ratio	5.78
P/TBV Ratio	6.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.77
EV / Sales	142.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.61

Financial Position

The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.58.

Current Ratio	11.30
Quick Ratio	11.08
Debt / Equity	0.58
Debt / EBITDA	n/a
Debt / FCF	-1.33
Interest Coverage	-17.01

Financial Efficiency

Return on equity (ROE) is -95.28% and return on invested capital (ROIC) is -31.01%.

Return on Equity (ROE)	-95.28%
Return on Assets (ROA)	-28.23%
Return on Invested Capital (ROIC)	-31.01%
Return on Capital Employed (ROCE)	-30.85%
Revenue Per Employee	8,482
Profits Per Employee	-112,118
Employee Count	110
Asset Turnover	0.03
Inventory Turnover	0.86

Taxes

Income Tax	-321,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.30% in the last 52 weeks. The beta is 1.03, so 4basebio's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	-40.30%
50-Day Moving Average	1,123.30
200-Day Moving Average	1,223.28
Relative Strength Index (RSI)	3.39
Average Volume (20 Days)	795

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 4basebio had revenue of GBP 933,000 and -12.33 million in losses. Loss per share was -0.94.

Revenue	933,000
Gross Profit	630,000
Operating Income	-12.79M
Pretax Income	-12.65M
Net Income	-12.33M
EBITDA	-12.04M
EBIT	-12.79M
Loss Per Share	-0.94

Full Income Statement

Balance Sheet

The company has 34.83 million in cash and 15.22 million in debt, giving a net cash position of 19.61 million or 1.27 per share.

Cash & Cash Equivalents	34.83M
Total Debt	15.22M
Net Cash	19.61M
Net Cash Per Share	1.27
Equity (Book Value)	26.38M
Book Value Per Share	1.70
Working Capital	33.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.74 million and capital expenditures -697,000, giving a free cash flow of -11.44 million.

Operating Cash Flow	-10.74M
Capital Expenditures	-697,000
Free Cash Flow	-11.44M
FCF Per Share	-0.74

Full Cash Flow Statement

Margins

Gross Margin	67.52%
Operating Margin	-1,371.17%
Pretax Margin	-1,356.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.47%
Shareholder Yield	n/a
Earnings Yield	-8.09%
FCF Yield	-7.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

4basebio has an Altman Z-Score of 3.79 and a Piotroski F-Score of 3.

Altman Z-Score	3.79
Piotroski F-Score	3